CYTOR and gastric cancer: Lastly, linc00152 is upregulated in various cancers including gastric cancer [145,147,352,353], lung cancer [144], gall bladder cancer [148,149], renal cell carcinoma [354], and pancreatic cancer [355], whilst its expression has been found to be downregulated in colorectal cancer [356].